FDA issues warning over Philips fetal monitors

Justine Varieur Cadet | | Health Imaging | Screening
The FDA has issued a letter to notify healthcare professionals and facilities of a number of complaints of inaccurate readings when using the Philips Healthcare Avalon fetal monitors, models FM20, FM30, FM40, and FM50 with the ultrasound transducer to measure fetal heart rate.

On Sept. 4, Philips issued an important device safety alert. Inaccurate output readings, if not properly addressed, may lead to unnecessary interventions, failure to identify the need for interventions and failure to identify fetal distress, according to the company.

The complaints most commonly occur during the second stage of labor, the agency reported. Philips received a number of complaints of inaccurate output readings that prompted this alert.

Justine Varieur Cadet

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.